Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PLD2 | O14939 | 1/20 | 0.43 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657637 | 0.89 | CCR3 (0.60) | RAB9ACXCR4CYP1A2CYP2C19CCR3 | |
| SCHEMBL5656854 | 0.87 | CCR3 (0.53) | RAB9ACXCR4CYP1A2CYP2C19CCR3 | |
| SCHEMBL5655951 | 0.83 | CXCR4 (0.48) | RAB9ACXCR4CYP1A2CYP2C19CCR3 | |
| SCHEMBL5102691 | 0.74 | HRH3 (0.50) | RAB9ACCR3MEN1KMT2AHRH3 | |
| SCHEMBL5654782 | 0.74 | CCR3 (0.59) | RAB9ACCR3MEN1KMT2ANPC1 | |
| SCHEMBL5657759 | 0.74 | HRH3 (0.53) | RAB9ACCR3MEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL5658393 | 0.72 | CCR3 (0.57) | RAB9ACCR3MEN1KMT2ANPC1 | |
| SCHEMBL5098799 | 0.72 | CCR3 (0.48) | CCR3HRH3PLD2PLD1 | |
| SCHEMBL5658287 | 0.72 | CCR3 (0.56) | CCR3KMT2AHRH3PLD2PLD1 | |
| SCHEMBL5655801 | 0.71 | GPR6 (0.49) | RAB9ACCR3MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | RAB9A 1454/4885CXCR4 22/4885CYP1A2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.